Ardena, a prominent Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical sector, is expanding its Bioanalytical Services in the Netherlands in a substantial way. The company’s latest strategic initiatives involve establishing a state-of-the-art bioanalytical laboratory at the Pivot Park facility in Oss. This new laboratory is projected to become fully operational by the first quarter of 2025. The facility will span more than 3,000 square feet and will offer highly advanced analytical testing services for both small and large biological molecules. Utilizing sophisticated technologies like LC-MS/MS, fluorometric detection assays, and the ELISA-based Gyrolab automated technology platform, Ardena aims to significantly elevate the precision and efficiency of its bioanalytical capabilities.
In addition to the new facility in Oss, Ardena is also boosting its existing Bioanalytical Center of Excellence located in Assen. This upgrade involves expanding the center’s capacity in immunochemistry, flow cytometry, and qPCR platforms, thus fortifying its ability to conduct comprehensive bioanalytical testing. Part of this robust expansion includes an increased capacity for LC-MS/MS and the incorporation of new Hamilton automated systems. With these advancements, Ardena aims to better meet the growing demand for its services while providing greater project flexibility and faster turnaround times. These enhancements not only cater to the current market needs but also position Ardena as a more versatile player in the bioanalytical services sector.
Expanding to Meet Diverse Client Needs
Ardena, a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry, is significantly enhancing its Bioanalytical Services in the Netherlands. This endeavor includes setting up a state-of-the-art bioanalytical lab at the Pivot Park facility in Oss, expected to be fully operational by the first quarter of 2025. Covering over 3,000 square feet, the facility will provide cutting-edge analytical testing for both small and large biological molecules. Advanced technologies like LC-MS/MS, fluorometric detection assays, and the ELISA-based Gyrolab automated platform will boost the precision and efficiency of Ardena’s bioanalytical services.
Beyond Oss, Ardena is also scaling up its existing Bioanalytical Center of Excellence in Assen. This upgrade enhances the center’s capacity in immunochemistry, flow cytometry, and qPCR platforms, allowing for comprehensive bioanalytical testing. It includes increased LC-MS/MS capabilities and new Hamilton automated systems. These advancements aim to meet growing service demands, offering greater project flexibility and faster turnaround times. This expansion not only addresses current market needs but also strengthens Ardena’s position as a versatile leader in bioanalytical services.
